INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership…
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells…
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1],…
Retrieve a Patient’s Longitudinal Health Record in Seconds to Confirm Study Eligibility & Query Population Cohorts via the Admin PortalSAN…
Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trialMELBOURNE, AUSTRALIA / ACCESSWIRE…
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences…
Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated…
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage…
iStopMM team members Thorir Einarsson Long, Jon Thorir Oskarsson, and Sæmundur Rognvaldsson are 2023 ASH Abstract Achievement AwardeesSTUDIO CITY, Calif.,…
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…